Lantern Pharma (LTRN) Receivables - Accured (2021 - 2026)

Lantern Pharma's (LTRN) quarterly Receivables - Accured came in at $32000.0 in Q1 2026, up 6.67% on a QoQ basis from $30000.0 in Q4 2025.

Lantern Pharma (LTRN) Receivables - Accured (2021 - 2026) Analysis & Trends

Lantern Pharma (LTRN) has 6 years of Receivables - Accured data on file, last reported at $32000.0 in Q1 2026.

Quarterly Receivables - Accured changed N/A year-over-year to $32000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32000.0 (changed N/A YoY) and the FY2025 annual result came in at $30000.0, down 69.07% from the prior year.
Receivables - Accured advanced to $32000.0 in Q1 2026, from $30000.0 in the prior quarter.
In the past five years, Receivables - Accured ranged from a high of $860000.0 in Q4 2023 to a low of $30000.0 in Q4 2025.
A 5-year average of $310375.0 and a median of $266500.0 in 2022 frame the typical range for Receivables - Accured.
Annual changes were most pronounced in 2022 — Receivables - Accured surged 346.05% — and 2024, when it slumped 88.72%.
Tracing LTRN's Receivables - Accured over 5 years: stood at $592000.0 in 2022, then surged by 45.27% to $860000.0 in 2023, then tumbled by 88.72% to $97000.0 in 2024, then sank by 69.07% to $30000.0 in 2025, then advanced by 6.67% to $32000.0 in 2026.
The last three Receivables - Accured figures came in at $32000.0 (Q1 2026), $30000.0 (Q4 2025), and $97000.0 (Q4 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables - Accured (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	-
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	-
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-
10	Lantern Pharma	26.11 Mn	26.11 Mn	-	32,000.00

Download Data